Neurosearch A/s

Poseidon Pharmaceuticals A/s

Søren Peter Olesen

Palle Christophersen

Lene Teuber

Philip K Ahring

Tino Dyhring Jørgensen

Bo Skaaning Jensen

Dorte Strøbæk

Joachim Demnitz

Camilla Ærteberg Bæk

Morten Grunnet

Rie S Hansen

Lars Siim Madsen

Annette Lauridsen

Dorte Strøbaek

This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

ERG channel openers for the treatment of cardiac arrhythmias

Certain 1,5-disubstituted benzimidazol-2-one compounds useful as therapeutic agents. The compounds may be of the Formula I wherein: R' represents hydrogen or alkyl; R&#x2033; represents halogen or trihalogenmethyl; and Hlg represents halogen; provided, however, that if Hlg is F, then R&#x2033; is not Cl. Also, use of the 1,5-disubstituted benzimidazol-2-one compounds, or pharmaceutically-acceptable addition salts thereof, in applications that benefit from increasing the blood-brain barrier permeability.

Benzimidazol-2-one derivatives and their use

The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SKCa and IKCa channels. In further aspects, the present invention relates to the use of these SK/IK channel activating agents for the manufacture of medicaments and pharmaceutical compositions comprising the SK/IK channel activating agents. The SK/IK channel activating agents of the invention are useful for the treatment or alleviation of diseases and conditions associated with the SK/IK channels, in particular respiratory diseases such as asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.

Use of isatin derivatives as ion channel activating agents

Growing community of inventors

Klampenborg, Denmark

Søren Peter Olesen